NASDAQ:VIE - Nasdaq -
53.01
0 (0%)
The current stock price of VIE is 53.01 null. In the past month the price increased by 0.38%. In the past year, price increased by 35.64%.
Viela Bio Inc. is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases. Viela Bio Inc. is headquartered in Gaithersburg, Maryland.
Viela Bio Inc
1 MEDIMMUNE WAY
GAITHERSBURG MD 20878
CEO: Zhengbin (Bing) Yao
Phone: 240-780-6356
The current stock price of VIE is 53.01 null.
The exchange symbol of Viela Bio Inc is VIE and it is listed on the Nasdaq exchange.
VIE stock is listed on the Nasdaq exchange.
Viela Bio Inc (VIE) has a market capitalization of 2.91B null. This makes VIE a Mid Cap stock.
Viela Bio Inc (VIE) has a support level at 52.97 and a resistance level at 53.14. Check the full technical report for a detailed analysis of VIE support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VIE does not pay a dividend.
Viela Bio Inc (VIE) will report earnings on 2022-02-08, after the market close.
Viela Bio Inc (VIE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.83).
ChartMill assigns a technical rating of 8 / 10 to VIE. When comparing the yearly performance of all stocks, VIE turns out to be only a medium performer in the overall market: it outperformed 41.15% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to VIE. While VIE seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months VIE reported a non-GAAP Earnings per Share(EPS) of -2.83. The EPS increased by 59.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -1293.07% | ||
ROA | -35.6% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 70% to VIE. The Buy consensus is the average rating of analysts ratings from 4 analysts.